FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’ - Fierce Pharma

What the report says

FiercePharma reported that the U.S. Food and Drug Administration has approved Simtriyo, Otsuka Pharmaceutical’s once-daily extended-release capsule for attention-deficit/hyperactivity disorder. The medicine, also known as centanafadine, is described in the report as the first approved drug in a class that inhibits reuptake of norepinephrine, dopamine and serotonin, or an NDSRI.

The approval positions the Japanese drugmaker for what FiercePharma characterized, citing the company’s framing, as its “next major CNS launch.” Otsuka already has a significant presence in central nervous system medicines, and Simtriyo adds a new branded product to that portfolio. The available source material does not specify the approved patient population, launch timing, pricing, clinical trial results or label details.

ADHD is commonly managed with behavioral strategies and medicines, including stimulant and nonstimulant options. A therapy with a distinct mechanism can matter because patients vary in tolerability, response and medical needs, and clinicians often weigh multiple factors when choosing treatment. The FDA’s decision therefore gives prescribers another approved option, though the practical impact will depend on the final label, payer coverage, physician uptake and post-approval experience.

This digest is based on the FiercePharma headline and accessible snippet because the full public article text was unavailable. Further editorial review should confirm the FDA label, indication details and any company statements before publication.